Patent SG-11201901830U-A (SG)
Title: nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS
Inventor: YOST CHRISTIAN CON
IPC: C07K14/47
Filed: 2017-09-05
Abstract: WO 18/0 45 37 1 A3 (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 March 2018 (08.03.2018) W I PO I PC T omit ° oI0IIIIIIIIIIH1011 111EI111°111 (10) International Publication Number WO 2018/045371 A3 (51) International Patent Classification: A61K 38/00 (2006.01) A61K 47/60 (2017.01) A61K 38/57 (2006.01) CO7K 14/47 (2006.01) A61K 47/48 (2006.01) (21) International Application Number: PCT/US2017/050072 (22) International Filing Date: 05 September 2017 (05.09.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/383,243 02 September 2016 (02.09.2016) US 62/492,019 28 April 2017 (28.04.2017) US (71) Applicant: THE UNIVERSITY OF UTAH RESEARCH FOUNDATION [US/US]; 615 Arapeen Drive, Suite 310, Salt Lake City, Utah 84108 (US). (72) Inventors: YOST, Christian Con; 615 Arapeen Drive, Suite 310, Salt Lake City, Utah 84108 (US). ZIMMER- MAN, Guy A.; 615 Arapeen Drive, Suite 310, Salt Lake City, Utah 84108 (US). WEYRICH, Andrew S.; 615 Ara- peen Drive, Suite 310, Salt Lake City, Utah 84108 (US). SCHIFFMAN, Joshua; 615 Arapeen Drive, Suite 310, Salt Lake City, Utah 84108 (US). (74) Agent: GIDDINGS, Barton W.; STOEL RIVES LLP, 201 So. Main Street, Suite 1100, One Utah Center, Salt Lake City, Utah 84111 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (88) Date of publication of the international search report: 12 April 2018 (12.04.2018) (54) Title: nNIF AND nNIF-RELATED PEPTIDES AND RELATED METHODS 100 80 - 60 - 40 - 20 - 0 0 I Percent survival 10 20 30 40 50 Hours No treatment FIG. 9A LPS CRISPP-LPS nNIF-LPS CRISPP-SCR-LPS (57) : Neonatal NET-Inhibitory Factor (nNIF) and nNIF-Related Peptides (NRPs) are provided. Methods for the treatment of and prophylaxis against inflammatory disorders and cancer are also provided. Additionally, methods for the inhibition of metastasis in patients having cancer are provided. The methods can include administering nNIF and/or a NRP to patients having, or at risk of developing, an inflammatory disorder or a cancer.